Price Hikes Not Supported by New Evidence for 8 of 10 High-Cost Drugs, Says ICER

Eight of 10 high-cost drugs — with increases that totaled $1.27 billion — had substantial price increases in 2022 that were not supported by new clinical evidence, a new report shows.

The Institute for Clinical and Economic Review’s (ICER) analysis found that one of three Medicare Part B drugs with recent high list price increases lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $680 per year.

The list of eight high-cost drugs with recent unsupported price increases was topped by AbbVie’s Humira (adalimumab), whose wholesale acquisition cost (WAC) increased by 7.11 percent from 2021 to 2022, while its net price went up 1.95 percent, representing an added cost of $386 million to patients during that time in the U.S.

Read the ICER report here.

To read the whole story, click here to subscribe.

Related Topics